52 Small Cap Stocks Just Made New 52-Week Highs
Strength in the small-cap space is concentrated in one particular industry, raising questions about valuation.
Strength in the small-cap universe is clustered in Biotechnology, which placed 11 names on today’s list. As of Monday, August 10, a total of 52 Small Cap stocks are at their strongest prices of the last year. The largest company on the list is Brinker International (EAT), with a market value of about $9.8 billion and a 22.8% gain over the last month. The central question is whether the underlying business growth can support these new highs.
Protagonist Therapeutics (PTGX) stands out for its high valuation, supported by revenue that grew 34.8% over the last twelve months and an operating margin of 20.7%. Elsewhere in the biotech sector, Crinetics Pharmaceuticals (CRNX) shows an even more extreme profile, with revenue growth of 2928.4% over the last twelve months paired with a negative operating margin of -1302.5%. These figures highlight the divergence between top-line expansion and current profitability among the day’s leaders.
The 10 Largest, By Market Cap
The table below shows the 10 largest of the 52 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| EAT | $9.8 Bil | 1.0% | 1.0% | 22.8% | 42.7% |
| PTGX | $9.8 Bil | 2.8% | 13.4% | 14.1% | 194.3% |
| BIO | $9.6 Bil | 0.6% | 5.9% | 19.7% | 33.7% |
| HQY | $9.0 Bil | 2.1% | 2.3% | 13.1% | 16.3% |
| CRNX | $8.8 Bil | 0.1% | 0.5% | 0.7% | 201.8% |
| NEU | $8.5 Bil | 2.3% | 6.5% | 19.1% | 27.7% |
| SYRE | $8.3 Bil | 0.4% | 11.0% | 7.8% | 591.1% |
| VSXY | $8.1 Bil | 1.5% | 12.2% | 27.6% | 361.1% |
| LQDA | $8.0 Bil | 0.9% | 8.6% | 16.8% | 373.9% |
| AVT | $8.0 Bil | 0.9% | 9.6% | 11.8% | 94.6% |
A new high is a starting point for research, not a conclusion.
A list of stocks at their 52-week highs is a useful screen for strength. But a price is not a verdict on a company’s quality or future. The disciplined approach is to treat a new high as an alert. It signals that the market is optimistic, but it is the investor’s job to open the books and determine if the business fundamentals truly earn the new valuation.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
One more pattern worth noticing: 26 of the 52 names are Health Care stocks. When a whole group is making new highs together, a biotech ETF like XBI is one way to own the group’s strength without betting on which single name leads it from here.
New Highs Fade. Discipline Compounds
Some of the names on this list will keep setting highs for years, and some are at the top of their run right now. Sorting one from the other, name by name, every day, is the work most investors never keep up with.
That sorting is what the Trefis High Quality (HQ) Portfolio does systematically: about 30 quality businesses screened for the fundamentals that sustain a run, held with rules instead of excitement. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Use the high list for ideas; use the portfolio for the compounding.